Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway

Molecular Therapy

Volumn 12, Issue 5, 2005, Pages 960-968

  Cheng, Wen Fang ^a   Lee, Chien Nan ^a   Chang, Ming Cheng ^a   Su, Yi Ning ^a   Chen, Chi An ^a   Hsieh, Chang Yao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

DNA vaccine; Fas; Fas ligand; Human papillomavirus; Tumor evasion

Indexed keywords

CALRETICULIN; DNA VACCINE; FAS ANTIGEN; FAS LIGAND; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTECTION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIGENS, CD95; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTORS; VACCINES, DNA;

ANIMALIA; HUMAN PAPILLOMAVIRUS; MURINAE;

EID: 27744567023     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.04.020     Document Type: Article

References (49)

1. M. Durst L. Gissmann H. Ikenberg and H. zur Hausen A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions Proc. Natl. Acad. Sci. USA 80 1983 3812-3815
2. F.X. Bosch et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group J. Natl. Cancer. Inst. 87 1995 796-802
3. D.M. Pardoll Cancer vaccines Nat. Med. 4 1998 525-531
4. W.F. Cheng et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene J. Immunol. 166 2001 6218-6226
5. N.P. Restifo et al. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I J. Immunother. 14 1993 182-190
6. N. Seki et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin J. Immunol. 168 2002 3484-3492
7. C. Beck H. Schreiber and D. Rowley Role of TGF-beta in immune-evasion of cancer Microsc. Res. Tech. 52 2001 387-395
8. M. Urosevic and R. Dummer HLA-g and IL-10 expression in human cancer-Different stories with the same message Semin. Cancer. Biol. 13 2003 337-342
9. W.F. Cheng et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen J. Clin. Invest. 108 2001 669-678
10. A. Serrano et al. A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells Immunogenetics 51 2000 1047-1052
11. E.K. Mikaelsdottir et al. HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958-1960 and 1995-1996 Gynecol. Oncol. 89 2003 22-30
12. + T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination Gene Ther. 10 2003 1311-1320
13. K.-Y. Lin et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen Cancer Res. 56 1996 21-26
14. C.K. Behrens F.H. Igney B. Arnold P. Moller and P.H. Krammer CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice J. Immunol. 166 2001 3240-3247
15. C.F. Hung et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen Cancer Res. 61 2001 3698-3703
16. C.F. Hung et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes Cancer Res. 63 2003 2393-2398
17. M.M. Simon et al. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis J. Immunol. 165 2000 3663-3672
18. M.H. Ryan J.A. Bristol E. McDuffie and S.I. Abrams Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope J. Immunol. 167 2001 4286-4292
19. S.A. Caldwell M.H. Ryan E. McDuffie and S.I. Abrams The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases J. Immunol. 171 2003 2402-2412
20. B. Gansbacher R. Bannerji B. Daniels K. Zier K. Cronin and E. Gilboa Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity Cancer Res. 50 1990 7820-7825
21. H. Hock M. Dorsch U. Kunzendorf Z. Qin T. Diamantstein and T. Blankenstein Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma Proc. Natl. Acad. Sci. USA 90 1993 2774-2778
22. K. Hung R. Hayashi A. Lafond-Walker C. Lowenstein D. Pardoll and H. Levitsky The central role of CD4(+) T cells in the antitumor immune response J. Exp. Med. 188 1998 2357-2368
23. A. Prevost-Blondel M. Neuenhahn M. Rawiel and H. Pircher Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen Eur. J. Immunol. 30 2000 2507-2515
24. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells Immunity 12 2000 677-686
25. + tumor-infiltrating lymphocytes J. Exp. Med. 173 1991 647-658
26. C. Becker et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay Nat. Med. 7 2001 1159-1162
27. D.M. Klinman G. Yamshchikov and Y. Ishigatsubo Contribution of CpG motifs to the immunogenicity of DNA vaccines J. Immunol. 158 1997 3635-3639
28. Z.K. Ballas W.L. Rasmussen et al. A.M. Krieg Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA J. Immunol. 157 1996 1840-1845
29. T. Sparwasser et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells Eur. J. Immunol. 28 1998 2045-2054
30. T. Jakob P.S. Walker A.M. Krieg M.C. Udey and J.C. Vogel Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA J. Immunol. 161 1998 3042-3049
31. S. Nagata and P. Golstein The Fas death factor Science 267 1995 1449-1456
32. J. Fellenberg H. Mau C. Scheuerpflug V. Ewerbeck and K.M. Debatin Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines Int. J. Cancer 72 1997 536-542
33. R. Watanabe-Fukunaga The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen J. Immunol. 148 1992 1274-1279
34. M. Weller K. Frei P. Groscurth P.H. Krammer Y. Yonekawa and A. Fontana Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: Induction and modulation of sensitivity by cytokines J. Clin. Invest. 94 1994 954-964
35. E.C. Shin et al. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway Int. J. Cancer 93 2001 262-268
36. X. Xu X.Y. Fu J. Plate and A.S. Chong IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression Cancer Res. 58 1998 2832-2837
37. E.Y. Ahn G. Pan S.M. Vickers and J.M. McDonald IFN-gamma upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma Int. J. Cancer 100 2002 445-451
38. J.K. Lee et al. IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells J. Immunol. 164 2000 231-239
39. D. Rosen J.H. Li S. Keidar I. Markon R. Orda and G. Berke Tumor immunity in perforin-deficient mice: A role for CD95 (Fas/APO-1) J. Immunol. 164 2000 3229-3235
40. + CTL J. Immunol. 164 2000 4941-4954
41. M.M. Keane et al. Fas expression and function in normal and malignant breast cell lines Cancer Res. 56 1996 4791-4798
42. P.H. Krammer P.R. Galle P. Moller and K.M. Debatin CD95(APO-1/ Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells Adv. Cancer Res. 75 1998 251-273
43. L. Owen-Schaub H. Chan J.C. Cusack J. Roth and L.L. Hill Fas and Fas ligand interactions in malignant disease Int. J. Oncol. 17 2000 5-12
44. S. Nagata Apoptosis by death factor Cell 88 1997 355-365
45. T. Suda et al. Expression of the Fas ligand in cells of T cell lineage J. Immunol. 154 1995 3806-3813
46. M.E. Dudley et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850-854
47. D.M. Pardoll Therapeutic vaccination for cancer Clin. Immunol. 95 2000 S44-S62
48. P. Romero et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes J. Exp. Med. 188 1998 1641-1650
49. T.F. Greten and E.M. Jaffee Cancer vaccines J. Clin. Oncol. 17 1999 1047-1060